Immunovant Sector: Pharmaceuticals and biotechnology (autoimmune and immunology therapeutics) HQ: 320 W 37th St., New York, NY Year Founded: 2018 Key Leaders: Eric Venker, MD, PharmD, CEO Number of Employees: 362 Stage: Public Financial Snapshot: $3.83 billion Notable Investors: SG Americas Securities, Roivant Sciences, RTW Investments, and BVF Partners Key Products: Immunovant is developing Batoclimab, an FcRn-targeting monoclonal antibody for autoimmune diseases (MG, TED, Graves disease), which is in Phase 3 registrational trials
Genetic overlap between somatic insulin-related and neuropsychiatric disorders
The common symptoms are painless swelling of the tongue and biting
The Data were analyzed using the Statistical Package for the Social Sciences version 27.0 (SPSS IBM Corp, Armonk, NY, USA)
The antioxidant is generally found in the liver as it attaches itself to the toxins that flow through the liver and takes them out of the body